Home Newsfeeds NeoGenomics Introduces Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics Introduces Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology

byBenzinga Newsdesk

May 28, 2024

1 minute read

NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31â€“June 4 (booth #31093).

$3.4 Million Bet On CrowdStrike Holdings? Check Out These 3 Stocks Insiders Are Buying

By Lisa Levin

January 9, 10:17 AM

Although US stocks closed sharply higher on Friday, there were a few notable insider trades.

COIN

M&A
News

Coeptis Therapeutics Secures Exclusive Rights To Negotiate To Acquire Transformational Cell Therapy Platform To Enable Potent Combinatorial Immuno-Oncology Treatment Strategies

By Happy Mohamed

March 29, 9:48 AM

Potential acquisition of VyGen-Bio would strengthen Coeptis' oncology pipeline by obtaining exclusive, worldwide ownership rights to GEAR™ Platform and companion diagnostic technologies WEXFORD,

COEP

Agenus Begins Mid-Stage Global Studies On Colorectal And Skin Cancer Candidate

By Ragothaman Srinivasan

September 12, 3:29 PM

Agenus (NASDAQ: AGEN) has initiated Phase 2 ACTIVATE trials of botensilimab to advance globally in metastatic patients who have progressed on available therapies. This global Phase 2 program include clinical trials of ACTIVATE-Colorectal and ACTIVATE-Melanoma studies.

AGEN